Growth Hormone Therapy in Heart Failure

Andrea Salzano, Alberto M. Marra, Roberta D'Assante, Michele Arcopinto, Toru Suzuki, Eduardo Bossone, Antonio Cittadini

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Several studies have shown that growth hormone (GH) deficiency is common in chronic heart failure and is associated with impaired functional capacity and poor outcomes. Data derived from animal models showed beneficial effects of GH treatment on peripheral vascular resistance, cardiac function, and survival. Despite this solid background, when translated onto the clinical field, these results did not lead to unequivocal results. This article focuses on the assessment of GH deficiency in chronic heart failure, the underlying molecular background, the impact on disease progression and outcomes, the effects of GH therapy, and the novel and more encouraging approach of GH-replacement therapy.

Original languageEnglish
Pages (from-to)501-515
Number of pages15
JournalHeart Failure Clinics
Volume14
Issue number4
DOIs
Publication statusPublished - Oct 1 2018

Fingerprint

Growth Hormone
Heart Failure
Vascular Resistance
Therapeutics
Hormone Replacement Therapy
Disease Progression
Animal Models

Keywords

  • Anabolic deficiency
  • Biomarker
  • Chronic heart failure
  • Growth hormone
  • Hormone deficiency
  • IGF-1
  • Novel therapies
  • Outcomes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Salzano, A., Marra, A. M., D'Assante, R., Arcopinto, M., Suzuki, T., Bossone, E., & Cittadini, A. (2018). Growth Hormone Therapy in Heart Failure. Heart Failure Clinics, 14(4), 501-515. https://doi.org/10.1016/j.hfc.2018.05.002

Growth Hormone Therapy in Heart Failure. / Salzano, Andrea; Marra, Alberto M.; D'Assante, Roberta; Arcopinto, Michele; Suzuki, Toru; Bossone, Eduardo; Cittadini, Antonio.

In: Heart Failure Clinics, Vol. 14, No. 4, 01.10.2018, p. 501-515.

Research output: Contribution to journalReview article

Salzano, A, Marra, AM, D'Assante, R, Arcopinto, M, Suzuki, T, Bossone, E & Cittadini, A 2018, 'Growth Hormone Therapy in Heart Failure', Heart Failure Clinics, vol. 14, no. 4, pp. 501-515. https://doi.org/10.1016/j.hfc.2018.05.002
Salzano, Andrea ; Marra, Alberto M. ; D'Assante, Roberta ; Arcopinto, Michele ; Suzuki, Toru ; Bossone, Eduardo ; Cittadini, Antonio. / Growth Hormone Therapy in Heart Failure. In: Heart Failure Clinics. 2018 ; Vol. 14, No. 4. pp. 501-515.
@article{b20a7ad977ac48a980aa96597a0928ae,
title = "Growth Hormone Therapy in Heart Failure",
abstract = "Several studies have shown that growth hormone (GH) deficiency is common in chronic heart failure and is associated with impaired functional capacity and poor outcomes. Data derived from animal models showed beneficial effects of GH treatment on peripheral vascular resistance, cardiac function, and survival. Despite this solid background, when translated onto the clinical field, these results did not lead to unequivocal results. This article focuses on the assessment of GH deficiency in chronic heart failure, the underlying molecular background, the impact on disease progression and outcomes, the effects of GH therapy, and the novel and more encouraging approach of GH-replacement therapy.",
keywords = "Anabolic deficiency, Biomarker, Chronic heart failure, Growth hormone, Hormone deficiency, IGF-1, Novel therapies, Outcomes",
author = "Andrea Salzano and Marra, {Alberto M.} and Roberta D'Assante and Michele Arcopinto and Toru Suzuki and Eduardo Bossone and Antonio Cittadini",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.hfc.2018.05.002",
language = "English",
volume = "14",
pages = "501--515",
journal = "Heart Failure Clinics",
issn = "1551-7136",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Growth Hormone Therapy in Heart Failure

AU - Salzano, Andrea

AU - Marra, Alberto M.

AU - D'Assante, Roberta

AU - Arcopinto, Michele

AU - Suzuki, Toru

AU - Bossone, Eduardo

AU - Cittadini, Antonio

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Several studies have shown that growth hormone (GH) deficiency is common in chronic heart failure and is associated with impaired functional capacity and poor outcomes. Data derived from animal models showed beneficial effects of GH treatment on peripheral vascular resistance, cardiac function, and survival. Despite this solid background, when translated onto the clinical field, these results did not lead to unequivocal results. This article focuses on the assessment of GH deficiency in chronic heart failure, the underlying molecular background, the impact on disease progression and outcomes, the effects of GH therapy, and the novel and more encouraging approach of GH-replacement therapy.

AB - Several studies have shown that growth hormone (GH) deficiency is common in chronic heart failure and is associated with impaired functional capacity and poor outcomes. Data derived from animal models showed beneficial effects of GH treatment on peripheral vascular resistance, cardiac function, and survival. Despite this solid background, when translated onto the clinical field, these results did not lead to unequivocal results. This article focuses on the assessment of GH deficiency in chronic heart failure, the underlying molecular background, the impact on disease progression and outcomes, the effects of GH therapy, and the novel and more encouraging approach of GH-replacement therapy.

KW - Anabolic deficiency

KW - Biomarker

KW - Chronic heart failure

KW - Growth hormone

KW - Hormone deficiency

KW - IGF-1

KW - Novel therapies

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=85051675624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051675624&partnerID=8YFLogxK

U2 - 10.1016/j.hfc.2018.05.002

DO - 10.1016/j.hfc.2018.05.002

M3 - Review article

C2 - 30266359

AN - SCOPUS:85051675624

VL - 14

SP - 501

EP - 515

JO - Heart Failure Clinics

JF - Heart Failure Clinics

SN - 1551-7136

IS - 4

ER -